- Preclinical evaluation of docusate as protective agent from herpes simplex viruses
Viridae Clinical Sciences, Inc, 1134 Burrard Street, Vancouver, British Columbia, V6Z 1Y8, Canada
Antiviral Res 52:25-32. 2001
..Docusate pretreatment of cells was associated with a 45% reduction in infectivity of those cells, despite a triple washing procedure. Once infected, an approximate 30% plaque reduction was observed with treatment...
- Evidence that the RNAseH activity of the duck hepatitis B virus is unable to act on exogenous substrates
Department of Molecular Microbiology and Immunology, St Louis University School of Medicine, 1402 South Grand Blvd, St Louis, MO 63104, USA
BMC Microbiol 1:12. 2001
..The mechanism of this template commitment is unknown. Here we provide evidence that the RNAseH activity of duck hepatitis B virus reverse transcriptase may also be unable to act on exogenous substrates...
- Evidence of dual sites of action of dendrimers: SPL-2999 inhibits both virus entry and late stages of herpes simplex virus replication
Viridae Clinical Sciences, Inc, 1134 Burrard Street, Vancouver, BC, Canada V6Z 1Y8
Antiviral Res 55:319-29. 2002
..Our data indicate that SPL-2999 is a potent inhibitor of both HSV-1 and -2 with the potential for further development as either a topical microbicide or a therapeutic agent...
- The synergistic effects of betulin with acyclovir against herpes simplex viruses
Viridae Clinical Sciences Inc, 1134 Burrard Street, Vancouver, BC, Canada V6Z 1Y8
Antiviral Res 64:127-30. 2004
..At the concentrations lower than these, additive effect was found. Synergistic antiviral effects were also found against HSV-2 at higher concentrations than for HSV-1, i.e. 0.45 microg/ml of ACV combined with 8.4 microg/ml of betulin...
- Identification of an essential molecular contact point on the duck hepatitis B virus reverse transcriptase
Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, 1402 S Grand Blvd, St Louis, MO 63104, USA
J Virol 79:10164-70. 2005
..Therefore, small-molecule ligands that compete for binding to T3 with its natural ligand could form a novel class of antiviral drugs...